# The Role of JAK Inhibitors in Pediatric Lichen Sclerosus et Atrophicus: A Case Report

## TL;DR

This case report shows that tofacitinib, a JAK inhibitor, effectively and safely treats lichen sclerosus in a child.

## Contribution

Demonstrates the efficacy of oral tofacitinib for pediatric lichen sclerosus et atrophicus.

## Key findings

- A pediatric patient with genital and extragenital LSA responded well to oral tofacitinib.
- Tofacitinib was found to be a safe treatment option for LSA in children.

## Abstract

Lichen sclerosus (LS) is an uncommon mucocutaneous condition that primarily affects the genitoanal region and is characterized by white, porcelain-like sclerotic lesions. Although its incidence peaks after menopause, LS can also occur in children, affecting both the genital and extragenital areas. We present the case of a pediatric patient with both genital and extragenital LS who responded well to oral tofacitinib therapy. This case highlights that oral tofacitinib is a safe and effective treatment option for lichen sclerosus et atrophicus (LSA) in the pediatric population.